Jon Wulff Petersen, CEO of Tech Transfer Office A/S, Denmark
Managing the Patent Portfolio
Patent budgets can easily get out of control – it is easy and relatively inexpensive to file a patent without thinking about the strength or value of the patent. In this session we explore patent strategy from the perspective of an experienced Tech Transfer Director.
Jari Romanainen, Executive Director
Activation, Tekes The role of Tekes in the Finnish innovation system Lauri Kangas, Senior Advisor Hormos Medical, Industrial Experiences from the Finnish System Jyrki Heino, Professor of Biochemistry, University of Turku, Scientific
Director, BioCity Turku, Biocentre The Researcher’s Point of View
Followed by a panel discussion including:
Markku Sjöstedt, Director Pre Seed Finance, Sitra
Finland has taken a very determined, systematic approach to converting Finland into a high-tech society. We present the important players in the Finnish innovation system.
Martin Raditsch, Head of Business Development, EMBL-EM, Germany
Konstantin Joanidopoulos, Head Special Applications, Olympus Bio-Systems GmbH, Germany Bridging the gap between academic research results and industry demands
Many promising technologies are just too early for licensing to established industrial partners and disappear in the "valley of death".
In this session solutions to this problem will be presented in the form of a case study. The technology provider and the industrial partner will describe the pros and cons of the adopted approach from their respective viewpoints.
Orion Pharma, Finland Does industry differ – a business perspective of patenting
Universities and companies approach patents from different perspectives – universities want to
protect technologies; companies want to protect products. How does
this difference affect the patenting strategy – and does the different
approach damage us when it comes to licensing to industry?
Jonathan Page, Head of New
Ventures, Imperial Innovations Ltd,
United Kingdom Bernhard Arnolds, ZFT – Zentralestelle
Universität Freiburg, Germany
The span of funding schemes for TTO ranges from low budget to stock
market floatation. We present two examples of rather early and quite
advanced schemes in Germany and the United Kingdom.
Petri Kalliokoski, Innovation
Director, VTT, Finland Anssi Rantasalo, CEO Kemppi,
Since innovation is non-linear, strong
partnerships between research and
industry can be a competitor to
traditional technology transfer. We
present the integrated innovation
system between VTT and the Finnish
Suni á Dalbø, Head of Commercialisation,
University of Aa1borg,
Denmark Experiences before and after a major deal making:
- How do you choose your partner? A
fair partner helps you realize the
value of an invention.
- Use of counselors (e.g. to help to
negotiate). Balance between own gut
feeling and external advise.
- How to handle the expectations
from the university & scientist after
Bronwyn H. Hall, Professor of the
Graduate School, University of
California at Berkeley & Professor of
Technology and Economy, University
of Maastricht, The Netherlands Dominique Foray, Professor of
Economy & Management of Innovation,
TTO has come to an age where
scientific studies of TTO is being
carried out. What can we, as TTO
professionals, learn from and
contribute to this research.
Leonard Fass, Director of Academic
Relations, GE Healthcare, United
Kingdom Patrick Nef, Chief Scientific Officer
& Chief Business Officer, Xytis
Pharmaceuticals Sàrl, Switzerland
As TTO professionals we tend to get
trapped in the linear model, and
often forget that innovation requires
tight collaboration with a business.
How do they go about innovation in a
globalised economy, and how does
that affect our thinking and the way in
which we can most effectively transfer
FRIDAY 2 JUNE PLENARY: 08:45 - 10:30
Laurent Mieville, Vice President ASTP, Main results of the ASTP 2006 survey & A new innovative and interactive platform for ASTP members Sue Tonks, Associate trainer and presenter Kintish, United Kingdom Working the Room
We spend a lot of our time networking inside and outside our universities. Few of us make the most of the opportunity or know how to follow up on the conversations we have or the people we meet. Here we learn the art of ‘Power Networking”
Catherine Mallalieu, Partner D-Young
& Co, United Kingdom Choosing and using your Patent Agent
In this session we focus in on the relationship between you and your
Patent Agent (Attorney). How should you choose them, manage
them and measure how good a job they’re doing? How should you brief
them and stay involved during the patent writing and examination
Vasilis Theoharakis, Associate
Professor Marketing & Entrepreneurship,
ALBA Greece & Senior Lecturer,
Aston University, United Kingdom Ioannis Arabatzis, CEO NanoPhos
and winner of the European Business
Plan Competition 2005, Greece
Because we have a shortage of entrepreneurs researchers need to become
more entrepreneurial and outside entrepreneurs need to be fed into our
start-ups. We introduce Venture Cups as a way of achieving this.
Steef Blok, Director Technology
Transfer Erasmus MC Holding
Rotterdam, The Netherlands Tol Trimborn, Director Corporate
Development DNage, the Netherlands
The University of Rotterdam has a successful TTO office. The Director of
the TTO office as well as the CEO of one of the start-ups bring us a specific success story.
Catherine Mallalieu, Partner DYoung
& Co, United Kingdom Getting the maximum ‘bang-per-buck’
Patenting can be hugely expensive once you get into the ‘national’
phase. How can you delay as long as possible to give you the maximum
time to license? If you have to ‘go national’ what coverage do licensees
expect you to have – what do companies do themselves?
Jeff Cope, Business Development Manager, RTI International, USA Taina Saksa, Innovation Manager, University of Helsinki, Finland
Issues such as the best times to educate faculty, the best topics to
cover with faculty, approaches for educating faculty, when and how to
use TTO website as an educational tool, and other do’s and don’ts related
to making sure faculty know their role in the tech transfer process.
Patrick Nef, Chief Scientific Officer
& Chief Business Officer, Xytis
Pharmaceuticals Sàrl, Switzerland Simon Crossley, Partner Eversheds
Solicitors, United Kingdom
We have had a strong focus on startups
as the primary alternative to
licensing deals. But we can also
develop the technology within the
university and then do a trade sell.
PLENARY: 15:30 - 16:45
Richard Jefferson, Chairman and CEO, CAMBIA and Founder, BiOS, Australia Claire T. Driscoll, Director, Technology Transfer Office NHGRI and NIH, USA
Some argue that, as public institutions, we should somehow build terms into our license agreements that ensure that
products based on our technologies are supplied at low cost to third world countries. Others say that this is not our
business and intervention is best left to governments and charities. In this final session we debate this serious issue and
explore whether there is anything we can or should be doing.
Please select the discussion tab of this page (top) to provide your feedback on the conference.